Murty Vundavalli, PhD

Specialties:
Clinical Genetics and Genomics (MD)

More specialties
Accepting New Patients

Profile Navigation

Overview
Schedule an Appointment
Credentials & Experience
Research

Overview

Email: vvm2@cumc.columbia.edu

Areas of Expertise / Conditions Treated

Cancer Genetics
Cytogenetic Study
Hematologic Malignancy
Karyotyping
Laboratory Based Translational Research
Molecular Diagnostics: Multiplex Amplification

Academic Appointments

Professor of Pathology and Cell Biology (in the Institute for Cancer Genetics) at CUMC

Administrative Titles

Director, Cancer Cytogenetics

Hospital Affiliations

NewYork-Presbyterian / Columbia University Irving Medical Center

Languages

Hindi
Telugu

Gender

Male

Schedule an Appointment

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.
Connect Sign In

Credentials & Experience

Education & Training

University of Delhi

Board Certifications

Clinical Genetics and Genomics (MD)

Honors & Awards

World Health Organization Fellow, Laboratory of Cancer Cytogenetics, Memorial Sloan Kettering Cancer Center, New York (1984-1985).

Research

Our laboratory is interested in understanding the genetic and epigenetic basis of cervical cancer and hematologic malignancies. One of the major goals is to make attempts to identify prognostic markers of response to treatment.

Carcinoma of uterine cervix is a common malignancy among women worldwide. Most cervical cancers are preceded by distinct preneoplastic epithelial changes providing opportunities to study genetic alterations at an early stage of transformation. Our genome-wide search for genetic and epigenetic alterations has identified several sites of copy number alterations, gene amplifications, and specific genetic pathways in invasive cancer. We are currently evaluating a predictive biomarker of apoptotic response to stratify patients that benefit combination drug therapy.
In leukemia and lymphoma, a similar strategy is applied to identify genetic and epigenetic predictive markers of response to treatment. Preclinical validations of a number of epigenetically inactivated markers are underway.

Selected Publications

Mathur D, Stratikopoulos E, Ozturk S, Steinbach N, Pegno S, Schoenfeld S, Yong R, Murty VV, Asara JM, Cantley LC, Parsons R. PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition. Cancer Discov. 2017 Mar 2. doi: 10.1158/2159-8290.CD-16-0612. [Epub ahead of print] PMID: 28255082
Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, Bhagat G, Zhang S, Pasqualucci L, Zhang L, Visco C, Dybkaer K, Chiu A, Orazi A, Zu Y, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, M??ller MB, Parsons BM, Winter JN, Piris MA, Westin J, Fowler N, Miranda RN, Ok CY, Li J, Medeiros LJ, Young KH. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis for activated B-cell-like diffuse large B-cell lymphoma. Leukemia. 31: 625-636, 2017. PMID 27568520
Margolskee E, Jobanputra V, Jain P, Chen J, Ganapathi K, Nahum O, Levy B, Morscio J, Murty V, Tousseyn T, Alobeid B, Mansukhani M, Bhagat G. Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders. Oncotarget. 7:37636-37648, 2016.
Ganapathi KA, Jobanputra V, Iwamoto F, Jain P, Chen J, Cascione L, Nahum O, Levy B, Xie Y, Khattar P, Hoehn D, Bertoni F, Murty VV, Pittaluga S, Jaffe ES, Alobeid B, Mansukhani MM, Bhagat G. The genetic landscape of dural marginal zone lymphomas. Oncotarget. 7:43052-43061, 2016.
Tannenbaum-Dvir S, Glade Bender JL, Church AJ, Janeway KA, Harris MH, Mansukhani MM, Nagy PL, Andrews SJ, Murty VV, Kadenhe-Chiweshe A, Connolly EP, Kung AL, Dela Cruz FS. Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000471.
Narayan G, Xie D, Ishdorj G, Scotto L, Mansukhani M, Pothuri B, Wright JD, Kaufmann AM, Schneider A, Arias-Pulido H, Murty VV. Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer. Genes Chromosomes Cancer. 55(2):177-89, 2016. PMID: 26542757
Shi D, Murty VV, Gu W. PCDH10, a novel p53 transcriptional target in regulating cell migration. Cell Cycle. 14: 857-866, 2015. PMID: 25590240
Gindin T, Murty V, Alobeid B, Bhagat G. MLL/KMT2A translocations in diffuse large B-cell lymphoma. Hematol Oncol 33:239-46, 2015. PMID: 25131304
Camacho CV, Todorova PK, Hardebeck MC, Tomimatsu N, Gil Del Alcazar CR, Ilcheva M, Mukherjee B, McEllin B, Vemireddy V, Hatanpaa K, Story MD, Habib AA, Murty VV, Bachoo R, Burma S. DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification. Oncogene. 34: 1064-1072, 2015. PMID: 24632607
Islam MA, Thomas SD, Murty VV, Sedoris KJ, Miller DM. c-Myc quadruplex-forming sequence Pu-27 induces extensive damage in both telomeric and non-telomeric regions of DNA. J Biol Chem. 289(12):8521-31, 2014. PMID: 24464582
Kode A, Manavalan JS, Mosialou I, Bhagat G, Rathinam CV, Luo N, Khiabanian H, Lee A, Murty VV, Friedman R, Brum A, Park D, Galili N, Mukherjee S, Teruya-Feldstein J, Raza A, Rabadan R, Berman E, Kousteni S. Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature. 506: 240-244, 2014. PMID: 24429522
Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB, Ouillette P, Trifonov V, Rossi D, Tabb?2 F, Ponzoni M, Chadburn A, Murty VV, Bhagat G, Gaidano G, Inghirami G, Malek SN, Rabadan R, Dalla-Favera R. Genetics of Follicular Lymphoma Transformation. Cell Rep. 6:130-40, 2014. PMID:24388756
Shah S, Schrader KA, Waanders E, Timms AE, Vijai J, Miething C, Wechsler J, Yang J, Hayes J, Klein RJ, Zhang J, Wei L, Wu G, Rusch M, Nagahawatte P, Ma J, Chen SC, Song G, Cheng J, Meyers P, Bhojwani D, Jhanwar S, Maslak P, Fleisher M, Littman J, Offit L, Rau-Murthy R, Fleischut MH, Corines M, Murali R, Gao X, Manschreck C, Kitzing T, Murty VV, Raimondi SC, Kuiper RP, Simons A, Schiffman JD, Onel K, Plon SE, Wheeler DA, Ritter D, Ziegler DS, Tucker K, Sutton R, Chenevix-Trench G, Li J, Huntsman DG, Hansford S, Senz J, Walsh T, Lee M, Hahn CN, Roberts KG, King MC, Lo SM, Levine RL, Viale A, Socci ND, Nathanson KL, Scott HS, Daly M, Lipkin SM, Lowe SW, Downing JR, Altshuler D, Sandlund JT, Horwitz MS, Mullighan CG, Offit K. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 45:1226-1231, 2013.
Narayan G, Xie D, Freddy AJ, Ishdorj G, Satwani P, Liyanage H, Clark L, Kisselev S, Nandula SV, Scotto L, Alobeid B, Savage D, Tycko B, O'Connor OA, Bhagat G, Murty VV.^. PCDH10 Promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis. Genes Chromosomes Cancer 52: 1030-1041, 2013.
Narayan G, Freddy AJ,Xie D,Liyanage H, Clark L, Kisselev S, Kang JU, Nandula SV, McGuinn C, Subramaniyam S, Alobeid B, Satwani P, Savage D, Bhagat G, Murty VV. Promoter Methylation-Mediated Inactivation of PCDH10 in Acute Lymphoblastic Leukemia Contributes to Chemotherapy Resistance. Genes, Chromosomes and Cancer 50: 1043-1053, 2011.


For a complete list of publications, please visit PubMed.gov